VALN - Valneva sells chikungunya vaccine priority review voucher for $103M
2024-02-05 04:31:14 ET
French vaccine maker Valneva ( NASDAQ: VALN ) said on Monday it sold the priority review voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for its chikungunya vaccine for $103M....
Valneva sells chikungunya vaccine priority review voucher for $103M